Summit Therapeutics

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Summit Therapeutics Inc. plans Datroway Phase III trial (öffnet in neuem Tab)

  Mugglehead Investment Magazine · 02.10.2026

• Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types (öffnet in neuem Tab)

  Investing News Network · 02.10.2026

• AstraZeneca and Daiichi Sankyo Partner with Summit Therapeutics to Study Datopotamab Deruxtecan and Ivonescimab (öffnet in neuem Tab)

  Oncodaily · 02.10.2026

• AstraZeneca, Daiichi Sankyo and Summit Therapeutics Plan Datroway–Ivonescimab Combination Trials (öffnet in neuem Tab)

  Yahoo Finance UK · 02.10.2026

• AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (öffnet in neuem Tab)

  Reuters · 02.10.2026

• AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo (öffnet in neuem Tab)

  Seeking Alpha · 02.10.2026

• AstraZeneca & Daiichi Sankyo announce clinical collaboration with Summit Therapeutics (öffnet in neuem Tab)

  TradingView · 02.10.2026

• Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway (öffnet in neuem Tab)

  Business Wire · 02.10.2026

• AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types (öffnet in neuem Tab)

  AstraZeneca · 02.10.2026

• Summit Therapeutics Is Maintained at Equal-Weight by Barclays (öffnet in neuem Tab)

  Moomoo · 01.10.2026

• What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership? (öffnet in neuem Tab)

  Yahoo Finance · 01.10.2026

• Summit Therapeutics Price Target Raised to $20.00/Share From $18.00 by Barclays (öffnet in neuem Tab)

  Moomoo · 01.10.2026

• Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Raises Target Price to $20 (öffnet in neuem Tab)

  Moomoo · 01.10.2026

• Summit Therapeutics Stock Climbs Wednesday: What's Happening? (öffnet in neuem Tab)

  TradingView · 30.09.2026

• AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets (öffnet in neuem Tab)

  24/7 Wall St. · 30.09.2026

• Leerink Partners Sticks to Its Hold Rating for Summit Therapeutics (SMMT) (öffnet in neuem Tab)

  The Globe and Mail · 30.09.2026

• H.C. Wainwright reiterates Summit Therapeutics stock rating as Neutral (öffnet in neuem Tab)

  Investing.com · 30.09.2026

• Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT) (öffnet in neuem Tab)

  The Globe and Mail · 30.09.2026

• AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll (öffnet in neuem Tab)

  BioSpace · 30.09.2026

• Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal (öffnet in neuem Tab)

  Investing.com · 30.09.2026

• AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics (öffnet in neuem Tab)

  Oncodaily · 30.09.2026

• AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up (öffnet in neuem Tab)

  Reuters · 30.09.2026

• AstraZeneca Backing Could Change The Case For Summit Therapeutics Stock (öffnet in neuem Tab)

  Simply Wall Street · 29.09.2026

• AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug (öffnet in neuem Tab)

  medcitynews.com · 29.09.2026

• AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says (öffnet in neuem Tab)

  Yahoo Finance · 29.09.2026

• Summit Therapeutics Rises as AstraZeneca Backs Ivonescimab With $2 Billion Investment (öffnet in neuem Tab)

  Quiver Quantitative · 29.09.2026

• Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab (öffnet in neuem Tab)

  Seeking Alpha · 29.09.2026

• AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology (öffnet in neuem Tab)

  Yahoo Finance · 29.09.2026

• Summit Shares Jump on $2B Strategic Investment From AstraZeneca (öffnet in neuem Tab)

  Yahoo Finance · 29.09.2026

• AstraZeneca Makes $2B Equity Investment in Summit Therapeutics (öffnet in neuem Tab)

  Contract Pharma · 29.09.2026